Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 28, 2020 at 12:02 AM.

  1. #1 cafead, Feb 28, 2020 at 12:02 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Sangamo Therapeutics (NASDAQ: SGMO) announced after the bell on Thursday that it signed a partnership with Biogen (NASDAQ: BIIB) to develop a number of gene-editing treatments. The scope of the agreement would focus on neurological and neuromuscular conditions, with an initial focus on treating Alzheimer's and Parkinson's diseases.

    article source
     
    Quote

Reply to Thread